197

Drug Discovery
Sub Categories on Drug Discovery
Latest Articles
Rules-based electronic triggers effectively ID missed opportunities in diagnosis

Rules-based electronic triggers effectively ID missed opportunities in diagnosis

by Lori SolomonRules-based electronic triggers (e-triggers) are useful for post hoc detection of missed opportunities in diagnosis (MODs) in emergency department visits, according to a study published

Rules-based electronic triggers effectively ID missed opportunities in diagnosis

by Lori SolomonRules-based electronic triggers (e-triggers) are useful for post hoc detection of missed opportunities in diagnosis (MODs) in emergency department visits, according to a study published
EU health agency urges stepped-up antibiotic resistance fight

EU health agency urges stepped-up antibiotic resistance fight

Methicillin-resistantStaphylococcus aureus. Credit: NIH/NIAIDThe European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, calling for a

EU health agency urges stepped-up antibiotic resistance fight

Methicillin-resistantStaphylococcus aureus. Credit: NIH/NIAIDThe European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, calling for a
Unexpected discovery revives abandoned breast cancer treatment

Unexpected discovery revives abandoned breast cancer treatment

byLund UniversityMolecular analyses of IGFBP7 expression in I-SPY2 and SCAN-B. Credit:npj Precision Oncology(2024). DOI: 10.1038/s41698-024-00712-9A recent study led by Lund Universi

Unexpected discovery revives abandoned breast cancer treatment

byLund UniversityMolecular analyses of IGFBP7 expression in I-SPY2 and SCAN-B. Credit:npj Precision Oncology(2024). DOI: 10.1038/s41698-024-00712-9A recent study led by Lund Universi
Weekly Update of Drug News-2/12/2025

Weekly Update of Drug News-2/12/2025

1.European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphomaOn November 19, 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has granted conditional marketing authorization for

Weekly Update of Drug News-2/12/2025

1.European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphomaOn November 19, 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has granted conditional marketing authorization for